-+ 0.00%
-+ 0.00%
-+ 0.00%

CORVUS PHARMACEUTICALS, - PRIMARY ENDPOINT IS SAFETY AND TOLERABILITY; KEY EFFICACY ENDPOINT IS HISCR 50/75 AT WEEK 12

Reuters·09/30/2026 20:07:09